Clinical Trials Logo
  1. Home
  2. Blepharospasm
  3. NCT00234507

Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm

Blepharospasm Clinical Trial

Official title:
Phase II, Multi-centre, Randomised, Double-blind, Parallel Group, Placebo-controlled Study to Assess the Efficacy and Safety of a Single Administration, by Subcutaneous Injection, of Three Doses of Dysport (40 Units/Eye, 80 Units/Eye, and 120 Units/Eye) for the Treatment of Benign Essential Blepharospasm

Clinical Trial Summary

The purpose of this study is to compare the effectiveness of 3 doses of Dysport® with placebo by assessing functional disability in blepharospasm.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00234507
Study type Interventional
Source Ipsen
Contact
Status Completed
Phase Phase 2
Start date January 2003
Completion date May 25, 2004
View Details
See also
  Status Clinical Trial Phase
Completed NCT01686061 - Blepharospasm Patient Survey for Patients With Blepharospasm
Completed NCT00535938 - MDs on Botox Utility (MOBILITY) N/A
Recruiting NCT05027997 - Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm Phase 2
Terminated NCT03263000 - Photic Blink Reflex in People With Blepharospasm and Increased Blinking
Completed NCT03938363 - Analysis of Gait Before and After Botulinum Toxin Treatment in Patients With Focal Dystonia N/A
Completed NCT02947815 - Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm Phase 2/Phase 3
Completed NCT00406367 - IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm Phase 3
Completed NCT00682760 - Comparison of Korean Botulinum Toxin Type A Versus Botox in the Treatment of Essential Blepharospasm Phase 3
Completed NCT00210431 - Post Marketing Surveillance Study of Dysport
Completed NCT05103202 - Efficacy and Safety of 10-Week or Shorter vs 12-Week or Longer Injection Intervals of Botulinum Toxin
Completed NCT04423341 - Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm Phase 2/Phase 3
Completed NCT03269123 - A Mechanical Device for Blepharospasm N/A
Completed NCT00411255 - Brain Stimulation to Treat Blepharospasm or Meige Syndrome Phase 2
Completed NCT00500799 - Brain Changes in Blepharospasm N/A
Completed NCT00761592 - Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm Phase 4
Completed NCT00001784 - Mexiletine for the Treatment of Focal Dystonia Phase 2
Recruiting NCT04939909 - Botulinum Toxin Relieves Anxiety, Depression and Sleep Disorderes in Patients With Blepharospasm Early Phase 1
Completed NCT03508882 - Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm Phase 4
Completed NCT01814774 - A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm N/A
Recruiting NCT05618470 - Wumeiwan Jiawei Fang Use in Patients With Blepharospasm Phase 2/Phase 3